Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADAPT+: Efgartigimod long-term safety in generalized myasthenia gravis
NCT03770403Phase 3Completed
- Sponsor
- argenx
- Start
- Mar 2019
- Primary completion
- Jun 2022
- Modality
- Antibody Fragments
- Countries
- 15
01
Overview
A Phase 3 trial of efgartigimod alfa in myasthenia gravis (MG), sponsored by argenx. Started Mar 2019; status: completed.
02
Drugs
efgartigimod alfa
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NCT03770403.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03770403.